ADL Amdl,

TUSTIN, Calif., Sept. 13 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has retained the statistical and regulatory consulting firm R. P. Chiacchierini & Associates, LLC, Rockville, Maryland, (http://www.rpcaconsulting.com/) to provide additional statistical analysis for the U.S. Food and Drug Administration (FDA) to support the Company's request for clearance to market its DR-70(R) cancer test kit in the U.S. R.P. Chiacchierini & Associates are experienced in all aspects of statistical consulting and regulatory affairs for device and biologic products. The Company, which has assisted more than 700 firms with their filings, employs former FDA senior management, policy makers, reviewers and other industry personnel. Dr. Chiacchierini, President and CEO, served in various management positions with the FDA and is co-author of a number of agency guidance documents. He served as Chief Scientific Officer in the U.S. Public Health Service under Surgeon General C. Everett Koop. "We are confident that R.P. Chiacchierini will provide the additional statistical analysis necessary for gaining clearance to market DR-70(R) from the FDA," said Gary Dreher, AMDL CEO. "The Company's primary objective remains receiving approval to market its DR-70(R) cancer test kit in the U.S., which will assist the Company's effort to market internationally." About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.rpcaconsulting.com/ Web site: http://www.amdl.com/

Copyright